Literature DB >> 19295479

Gamma-globulin levels in patients with community-acquired septic shock.

Fabio Silvio Taccone1, Patrick Stordeur, Daniel De Backer, Jacques Creteur, Jean-Louis Vincent.   

Abstract

Polyclonal intravenous immunoglobulins (IVIGs) can modulate the host immune response and may improve outcomes in some patients. In this prospective, noninterventional study, we assessed the time-course of gamma-globulin concentrations in 21 patients with septic shock and evaluated the relationship of gamma-globulin concentrations to disease severity and outcome. Six patients (28.5%) died. Sixteen patients (76%) had hypo-gamma-globulinemia at admission: 12 (57%) had low IgG concentrations (G650 mg/dL), 2 had low IgA concentrations (G70 mg/dL), and 9 had low IgM concentrations (G40 mg/dL). Two patients had low concentrations of all three gamma-globulins; these patients both died from refractory shock within 2 days. Patients with low IgG concentrations were indistinguishable at baseline from patients with normal IgG concentrations but had fewer vasopressor-free days (over 28 days) and more frequently developed acute lung injury/acute respiratory distress syndrome (3/9 vs. 10/12; P = 0.02). All deaths occurred in the patients with low IgG concentrations (6/ 12 vs. 0/9). There was a variable increase in kappa and lambda free light chains, a marker of gamma-globulin synthesis, over time with no significant difference between low and normal IgG groups. This pilot study indicates that low concentrations of gamma-globulins, especially IgG, are common in patients with community-acquired septic shock and persist over time even when sepsis resolves. Despite similar presentation, patients with hypo-IgG had greater vasopressor requirements, were more likely to develop acute lung injury/acute respiratory distress syndrome, and had higher mortality. Patients with low IgG concentrations may represent a logical target group to study the effects of Ig supplementation in septic shock.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295479     DOI: 10.1097/SHK.0b013e3181a2c0b2

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  24 in total

Review 1.  Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis.

Authors:  Manu Shankar-Hari; Nicholas Culshaw; Benjamin Post; Eduardo Tamayo; David Andaluz-Ojeda; Jesús F Bermejo-Martín; Sebastian Dietz; Karl Werdan; Richard Beale; Jo Spencer; Mervyn Singer
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

2.  The Japanese guidelines for the management of sepsis.

Authors:  Shigeto Oda; Mayuki Aibiki; Toshiaki Ikeda; Hitoshi Imaizumi; Shigeatsu Endo; Ryoichi Ochiai; Joji Kotani; Nobuaki Shime; Osamu Nishida; Takayuki Noguchi; Naoyuki Matsuda; Hiroyuki Hirasawa
Journal:  J Intensive Care       Date:  2014-10-28

Review 3.  The role of genetics and antibodies in sepsis.

Authors:  Evangelos J Giamarellos-Bourboulis; Steven M Opal
Journal:  Ann Transl Med       Date:  2016-09

4.  Presence of preexisting antibodies mediates survival in sepsis.

Authors:  Rituparna Moitra; Dominic R Beal; Bryan G Belikoff; Daniel G Remick
Journal:  Shock       Date:  2012-01       Impact factor: 3.454

5.  The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).

Authors:  Osamu Nishida; Hiroshi Ogura; Moritoki Egi; Seitaro Fujishima; Yoshiro Hayashi; Toshiaki Iba; Hitoshi Imaizumi; Shigeaki Inoue; Yasuyuki Kakihana; Joji Kotani; Shigeki Kushimoto; Yoshiki Masuda; Naoyuki Matsuda; Asako Matsushima; Taka-Aki Nakada; Satoshi Nakagawa; Shin Nunomiya; Tomohito Sadahiro; Nobuaki Shime; Tomoaki Yatabe; Yoshitaka Hara; Kei Hayashida; Yutaka Kondo; Yuka Sumi; Hideto Yasuda; Kazuyoshi Aoyama; Takeo Azuhata; Kent Doi; Matsuyuki Doi; Naoyuki Fujimura; Ryota Fuke; Tatsuma Fukuda; Koji Goto; Ryuichi Hasegawa; Satoru Hashimoto; Junji Hatakeyama; Mineji Hayakawa; Toru Hifumi; Naoki Higashibeppu; Katsuki Hirai; Tomoya Hirose; Kentaro Ide; Yasuo Kaizuka; Tomomichi Kan'o; Tatsuya Kawasaki; Hiromitsu Kuroda; Akihisa Matsuda; Shotaro Matsumoto; Masaharu Nagae; Mutsuo Onodera; Tetsu Ohnuma; Kiyohiro Oshima; Nobuyuki Saito; So Sakamoto; Masaaki Sakuraya; Mikio Sasano; Norio Sato; Atsushi Sawamura; Kentaro Shimizu; Kunihiro Shirai; Tetsuhiro Takei; Muneyuki Takeuchi; Kohei Takimoto; Takumi Taniguchi; Hiroomi Tatsumi; Ryosuke Tsuruta; Naoya Yama; Kazuma Yamakawa; Chizuru Yamashita; Kazuto Yamashita; Takeshi Yoshida; Hiroshi Tanaka; Shigeto Oda
Journal:  Acute Med Surg       Date:  2018-02-05

6.  Influence of the serum levels of immunoglobulins on clinical outcomes in medical intensive-care patients.

Authors:  C Geier; J Schröder; A Tamm; S Dietz; S Nuding; K Holder; Ö Khandanpour; K Werdan; H Ebelt
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-12-17       Impact factor: 0.840

7.  Serum IgG levels and mortality in patients with severe sepsis and septic shock : The SBITS data.

Authors:  S Dietz; C Lautenschläger; U Müller-Werdan; G Pilz; P Fraunberger; M Päsler; H Ebelt; A K Walli; K Werdan; S Nuding
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-09-27       Impact factor: 0.840

8.  Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock.

Authors:  Ilaria Cavazzuti; Giulia Serafini; Stefano Busani; Laura Rinaldi; Emanuela Biagioni; Marta Buoncristiano; Massimo Girardis
Journal:  Intensive Care Med       Date:  2014-09-13       Impact factor: 17.440

9.  Victims or Culprits, B Cells May Serve as Markers for Mortality Risk and Targeted Therapy in Sepsis.

Authors:  Zoltán Spolarics
Journal:  Crit Care Med       Date:  2017-11       Impact factor: 7.598

10.  The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).

Authors:  Osamu Nishida; Hiroshi Ogura; Moritoki Egi; Seitaro Fujishima; Yoshiro Hayashi; Toshiaki Iba; Hitoshi Imaizumi; Shigeaki Inoue; Yasuyuki Kakihana; Joji Kotani; Shigeki Kushimoto; Yoshiki Masuda; Naoyuki Matsuda; Asako Matsushima; Taka-Aki Nakada; Satoshi Nakagawa; Shin Nunomiya; Tomohito Sadahiro; Nobuaki Shime; Tomoaki Yatabe; Yoshitaka Hara; Kei Hayashida; Yutaka Kondo; Yuka Sumi; Hideto Yasuda; Kazuyoshi Aoyama; Takeo Azuhata; Kent Doi; Matsuyuki Doi; Naoyuki Fujimura; Ryota Fuke; Tatsuma Fukuda; Koji Goto; Ryuichi Hasegawa; Satoru Hashimoto; Junji Hatakeyama; Mineji Hayakawa; Toru Hifumi; Naoki Higashibeppu; Katsuki Hirai; Tomoya Hirose; Kentaro Ide; Yasuo Kaizuka; Tomomichi Kan'o; Tatsuya Kawasaki; Hiromitsu Kuroda; Akihisa Matsuda; Shotaro Matsumoto; Masaharu Nagae; Mutsuo Onodera; Tetsu Ohnuma; Kiyohiro Oshima; Nobuyuki Saito; So Sakamoto; Masaaki Sakuraya; Mikio Sasano; Norio Sato; Atsushi Sawamura; Kentaro Shimizu; Kunihiro Shirai; Tetsuhiro Takei; Muneyuki Takeuchi; Kohei Takimoto; Takumi Taniguchi; Hiroomi Tatsumi; Ryosuke Tsuruta; Naoya Yama; Kazuma Yamakawa; Chizuru Yamashita; Kazuto Yamashita; Takeshi Yoshida; Hiroshi Tanaka; Shigeto Oda
Journal:  J Intensive Care       Date:  2018-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.